- Home
- BTAI
as 12-18-2024 3:32pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 28.7M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 949.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $4.17 | Next Earning Date: | 11-14-2024 |
| Revenue: | $2,276,000 | Revenue Growth: | 83.25% |
| Revenue Growth (this year): | 164.86% | Revenue Growth (next year): | 69.74% |
Stock Insider Trading Activity of BioXcel Therapeutics Inc. (BTAI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Neill Vincent | BTAI | See Remarks | Dec 14 '24 | Sell | $0.35 | 165 | $58.13 | 19,957 | |
| Rodriguez Javier | BTAI | See Remarks | Dec 14 '24 | Sell | $0.36 | 430 | $153.02 | 24,643 | |
| Yocca Frank | BTAI | Chief Scientific Officer | Dec 14 '24 | Sell | $0.35 | 430 | $151.82 | 29,156 |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
GlobeNewswire
a month ago
BioXcel Therapeutics Announces Proposed Public Offering
GuruFocus.com
a month ago
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
Thomson Reuters StreetEvents
a month ago
Q3 2024 BioXcel Therapeutics Inc Earnings Call
Zacks
a month ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
GuruFocus.com
a month ago
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings
GlobeNewswire
a month ago
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.